Search results
Results From The WOW.Com Content Network
The drug policy of Germany is considered to be one of the most lenient among European Union (EU) countries. Policies vary depending on the state. History.
The following drugs are controlled by the German Narcotic Drugs Act (German: Betäubungsmittelgesetz or BtMG). Trade and possession of these substances without licence or prescription is considered illegal; prescription is illegal for drugs on Anlage I and II and drugs on Anlage III require a special prescription form.
Pervitin, an early form of methamphetamine, was widely used in Nazi Germany and was available without a prescription. [1]The generally tolerant official drug policy in the Third Reich, the period of Nazi control of Germany from the 1933 Machtergreifung to Germany's 1945 defeat in World War II, was inherited from the Weimar government which was installed in 1919 following the dissolution of the ...
The BtMG updated the German Opium Law 1929 and mirrors the Swiss BtMG and Austrian Suchtmittelgesetz. The German Narcotics Act was re-announced on 1 March 1994. [2] The last change to the law was the legalization of Cannabis in Germany on 1 April 2024. Since then, the handling of this drug has been subject to the German cannabis control bill. [3]
A German federal court on Tuesday denied two seriously ill men direct access to a lethal dose of a drug, arguing that the country's narcotics law stands in the way and that they could turn to ...
Germany's health ministry has no plans to change a law that prevents the health insurance system from paying for weight-loss drugs, it said on Tuesday, dismissing remarks by an Eli Lilly executive ...
In Germany, several laws govern drugs (both recreational and pharmaceutical). Narcotic Drugs Act (Betäubungsmittelgesetz, BtMG), regulates narcotics and contains explicit lists of those covered: Anlage I (authorized scientific use only), Anlage II (authorized trade only, not prescriptible) and Anlage III (special prescription form required).
Beyond Ozempic, German patients and medical insurances are among the main beneficiaries of drug parallel trade in the European Union because the country is the larget inbound market for EU drug ...